FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of AD-223

A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06052748
Enrollment
502
Registered
2023-09-25
Start date
2024-02-15
Completion date
2025-04-02
Last updated
2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Essential

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-223

Detailed description

Condition or disease : hypertension

Interventions

DRUGAD-223A

PO, Once daily(QD), 8weeks

DRUGAD-223B

PO, Once daily(QD), 8weeks

DRUGAD-223C

PO, Once daily(QD), 8weeks

DRUGAD-223A Placebo

PO, Once daily(QD), 8weeks

DRUGAD-223B Placebo

PO, Once daily(QD), 8weeks

DRUGAD-223C Placebo

PO, Once daily(QD), 8weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Other inclusions applied

Exclusion criteria

* Orthostatic hypotension with symptom * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
Change rate of MSSBPBaseline, Week 8Change from baseline in mean sitting systolic blood pressure

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026